Horizon Therapeutics

547 articles with Horizon Therapeutics

• 

  Horizon Bets $700 Million on Arrowhead's Gout RNAi Drug

  6/21/2021

  Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine. 

• Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)

  6/18/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021.

• Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology

  6/2/2021

  -- Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA® (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants -- -- Data on the company’s investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST --

• Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy

  5/27/2021

  Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA ® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit --

• Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology

  5/21/2021

  Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology -- Key presentations feature investigational programs in rheumatoid arthritis and data evaluating KRYSTEXXA ® (pegloticase injection) for people with uncontrolled gout who received a kidney transplant --

• Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®

  5/20/2021

  Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work ®

• Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company

  5/13/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company, and #2 in overall corporate reputation among U.S. patient groups familiar with the company.

• New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation

  5/6/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis of the pivotal Phase 2/3 N-MOmentum trial for UPLIZNA (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with NMOSD.

• Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary

  5/6/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare Businesswomen’s Association (HBA) Luminary. The HBA is the leading nonprofit global organization committed to furthering the advancement and impact of women in health c

• Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.

  5/5/2021

  -- First-Quarter 2021 Net Sales of $342.4 Million; First-Quarter 2021 GAAP Net Loss of $123.4 Million; Adjusted EBITDA of $45.8 Million -- -- First-Quarter 2021 Orphan Segment Net Sales Increased 5 Percent to $257.5 Million; KRYSTEXXA ® (pegloticase injection) First-Quarter 2021 Net Sales Increased 14 Percent to $106.7 Million --

• Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide

  4/27/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked #4 in overall corporate reputation among nearly 50 pharmaceutical and biotech companies based on PatientView’s annual survey of 1,920 patient groups worldwide.

• HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

  4/21/2021

    HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc

• New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)

  4/16/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD.

• New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

  4/16/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA® (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in The Lancet Diabetes & Endocrinology.

• Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®

  4/12/2021

  Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For ® - Company also named to the 2021 Best Places to Work in Chicago list by Crain’s Chicago Business -

• Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021

  4/8/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.

• New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting

  4/5/2021

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data will be presented at the American Academy of Neurology’s 73rd Annual Meeting, which will be held virtually April 17-22, 2021

• Horizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

  3/30/2021

  Horizon Therapeutics plc to Resupply Market With TEPEZZA ® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

• Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership

  3/29/2021

  Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as well as showcase their STEAM talents

• First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout

  3/25/2021

  First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA ® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout -- New Clinical Trial Complements Ongoing Efforts to Evolve the Patient Experience with KRYSTEXXA --